Smith & Nephew SNATS (NYSE:SNN) & FitLife Brands (NASDAQ:FTLF) Critical Comparison

FitLife Brands (NASDAQ:FTLF) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Valuation & Earnings

This table compares FitLife Brands and Smith & Nephew SNATS”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$64.47 million	2.29	$8.98 million	$0.57	27.63
Smith & Nephew SNATS	$5.81 billion	2.43	$412.00 million	N/A	N/A

Smith & Nephew SNATS has higher revenue and earnings than FitLife Brands.

Insider & Institutional Ownership

2.3% of FitLife Brands shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 61.4% of FitLife Brands shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares FitLife Brands and Smith & Nephew SNATS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FitLife Brands	9.57%	19.55%	10.51%
Smith & Nephew SNATS	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for FitLife Brands and Smith & Nephew SNATS, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	0	2	2	0	2.50
Smith & Nephew SNATS	0	7	0	1	2.25

FitLife Brands currently has a consensus price target of $23.00, suggesting a potential upside of 46.03%. Smith & Nephew SNATS has a consensus price target of $35.75, suggesting a potential upside of 7.39%. Given FitLife Brands’ stronger consensus rating and higher probable upside, equities analysts clearly believe FitLife Brands is more favorable than Smith & Nephew SNATS.

Risk & Volatility

FitLife Brands has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Smith & Nephew SNATS has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.

Summary

FitLife Brands beats Smith & Nephew SNATS on 7 of the 13 factors compared between the two stocks.

About FitLife Brands

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.